Investigational Long-Acting Form Of HIV Prevention Drug More Effective Than Daily Oral Pill Among MSM, Transgender Women, NIH Study Shows
NIH: Long-acting injectable form of HIV prevention outperforms daily pill in NIH study
“A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health…” (7/7).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.